Summit Therapeutics (SMMT)
NASDAQ:SMMT
US Market
Holding SMMT?
Track your performance easily

Summit Therapeutics (SMMT) Financial Statements

831 Followers

Summit Therapeutics Financial Overview

Summit Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.229; its P/E ratio is -92.47; Summit Therapeutics is scheduled to report earnings on October 30, 2024, and the estimated EPS forecast is $-0.07. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -57.28M$ -40.35M-$ -18.55M$ -12.20M
EBITDA$ -56.86M$ -40.33M-$ -16.76M$ -14.63M
Net Income Common Stockholders$ -60.38M$ -43.47M$ -36.57M$ -21.27M$ -14.72M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 325.47M$ 156.68M$ 186.24M$ 198.94M$ 215.01M
Total Assets$ 341.86M$ 176.78M$ 202.95M$ 218.48M$ 237.37M
Total Debt$ 108.70M$ 109.52M$ 106.10M$ 106.66M$ 107.26M
Net Debt$ -216.76M$ -47.16M$ -80.14M$ -92.29M$ -107.75M
Total Liabilities$ 146.78M$ 132.57M$ 125.26M$ 119.10M$ 117.77M
Stockholders Equity$ 195.07M$ 44.21M$ 77.69M$ 99.38M$ 119.60M
Cash Flow-
Free Cash Flow$ -33.06M$ -30.14M-$ -14.95M$ -29.07M
Operating Cash Flow$ -33.00M$ -30.13M$ -19.46M$ -14.90M$ -29.27M
Investing Cash Flow$ -200.08M$ 19.87M$ 60.57M$ -3.49M$ 207.00K
Financing Cash Flow$ 200.21M$ 485.00K$ 6.25M$ 229.00K$ -80.00K
Currency in USD

Summit Therapeutics Earnings and Revenue History

Summit Therapeutics Debt to Assets

Summit Therapeutics Cash Flow

Summit Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis